Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Lucid Diagnostics (LUCD) Return on Sales (2021 - 2025)

Lucid Diagnostics (LUCD) has disclosed Return on Sales for 5 consecutive years, with 8.6% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Sales rose 196.0% year-over-year to 8.6%, compared with a TTM value of 12.25% through Sep 2025, down 155.0%, and an annual FY2024 reading of 10.59%, up 1110.0% over the prior year.
  • Return on Sales was 8.6% for Q3 2025 at Lucid Diagnostics, down from 3.82% in the prior quarter.
  • Across five years, Return on Sales topped out at 41.93% in Q2 2021 and bottomed at 529.79% in Q4 2021.
  • Average Return on Sales over 5 years is 69.43%, with a median of 25.32% recorded in 2025.
  • Peak annual rise in Return on Sales hit 39650bps in 2022, while the deepest fall reached -15801bps in 2022.
  • Year by year, Return on Sales stood at 529.79% in 2021, then soared by 75bps to 133.29% in 2022, then skyrocketed by 92bps to 10.41% in 2023, then grew by 4bps to 10.03% in 2024, then rose by 14bps to 8.6% in 2025.
  • Business Quant data shows Return on Sales for LUCD at 8.6% in Q3 2025, 3.82% in Q2 2025, and 32.5% in Q1 2025.